Dago Bio completed $22 million in Series A financing
Dage Bio is a molecular glue targeted protein degradation technology and new drug developer. Starting from a new chemical skeleton discovered by Professor Cang Yong’s laboratory, it has created Lenalidomide, which is commonly used with other molecular glue companies. A unique compound library different from Pomalidomide derivatives, and through the company’s continuous exploration and data […]
Dago Bio completed $22 million in Series A financing Read More »